Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Pancreatic Neoplasms 6Prostatic Neoplasms 3Multiple Myeloma 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Rectal Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Melanoma 2Glioblastoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Solid Tumor 1Sarcoma, Clear Cell 1Refractory or Relapsed Solid Tumors 1Platinum-resistant Epithelial Ovarian Cancer 1Neoplasm Metastasis 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Klatskin Tumor 1Gliosarcoma 1Gastrointestinal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Arthritis, Rheumatoid 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Hydroxychloroquine × Clear all
NCT04163107 2022-03-18

MYELOMA-HCQ

Norwegian University of Science and Technology

Phase 1 Completed
19 enrolled
Plasma cell

Multiple Myeloma

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01689987 2017-09-07

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡